Country Trust Bank cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 283,602 shares of the company’s stock after selling 734 shares during the quarter. Country Trust Bank’s holdings in Eli Lilly and were worth $24,259,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Pathstone Family Office LLC grew its position in shares of Eli Lilly and by 100.0% during the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock valued at $4,774,000 after purchasing an additional 29 shares in the last quarter. Vantage Financial Partners Ltd. Inc. purchased a new position in shares of Eli Lilly and during the second quarter valued at about $494,000. Acrospire Investment Management LLC grew its position in shares of Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC purchased a new position in shares of Eli Lilly and during the second quarter valued at about $128,000. Finally, San Francisco Sentry Investment Group CA purchased a new position in shares of Eli Lilly and during the second quarter valued at about $129,000. 76.42% of the stock is currently owned by institutional investors and hedge funds.

Shares of Eli Lilly and Company (NYSE:LLY) traded up $0.22 during trading hours on Tuesday, hitting $86.67. The company’s stock had a trading volume of 3,336,800 shares, compared to its average volume of 3,672,243. Eli Lilly and Company has a fifty-two week low of $67.42 and a fifty-two week high of $89.09. The stock has a market capitalization of $95,189.66, a price-to-earnings ratio of 21.14, a PEG ratio of 1.90 and a beta of 0.35. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the previous year, the business earned $0.88 earnings per share. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. analysts expect that Eli Lilly and Company will post 4.21 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a dividend yield of 2.60%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s payout ratio is 98.58%.

In other news, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 190,000 shares of Eli Lilly and stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the sale, the insider now directly owns 123,682,287 shares of the company’s stock, valued at approximately $10,207,499,146.11. The disclosure for this sale can be found here. Insiders have sold 628,588 shares of company stock valued at $53,399,536 in the last 90 days. Company insiders own 0.20% of the company’s stock.

A number of brokerages have recently weighed in on LLY. BMO Capital Markets restated a “sell” rating and set a $71.00 price objective on shares of Eli Lilly and in a research report on Thursday, September 28th. Cowen restated a “buy” rating and set a $95.00 price objective on shares of Eli Lilly and in a research report on Wednesday, October 4th. Jefferies Group restated a “buy” rating and set a $89.00 price objective (down previously from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. BidaskClub lowered Eli Lilly and from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Finally, Piper Jaffray Companies restated a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a research report on Friday, October 13th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $90.25.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/eli-lilly-and-company-lly-holdings-reduced-by-country-trust-bank/1759521.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.